We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.30 | -1.06% | 27.98 | 27.975 | 27.98 | 28.385 | 27.81 | 28.345 | 123,292 | 13:15:31 |
From May 2019 to May 2024
By Michael Dabaie
ESSA Pharma Inc. said Wednesday it is in a clinical trial collaboration and supply agreement with Bayer.
ESSA, a clinical-stage pharmaceutical company, said the agreement is to evaluate its lead product candidate, EPI-7386, in combination with Bayer's darolutamide in patients with metastatic castration-resistant prostate cancer.
Under the agreement, Bayer may sponsor and conduct a Phase 1/2 study. ESSA said it will supply EPI-7386 for the trial and will retain all rights to EPI-7386. The clinical study is expected to start in 2021.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 28, 2021 08:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
